Acute Myocardial Infraction Epidemiology

• Acute myocardial infarction is myocardial necrosis resulting from acute obstruction of a coronary artery. 
• Among the 7MM, the United States reported the highest number of total incident cases of AMI in 2024, while Japan reported the lowest cases.
• Among the type-specific cases, NSTEMI accounted for major contribution nearly 60% of total cases, compared to STEMI in the EU4 and the UK in 2024.
• In EU4 and the UK, Germany is at the top of the ladder, followed by Italy and the UK, while Spain is at the bottom of the ladder.
• The incidence of AMI was higher in men than in women; several risk factors were more strongly associated with AMI in women compared with men.
• The increasing use of cardiac biomarkers for diagnosing AMI during the past two decades and the changing cutoff levels for the laboratory tests used to define myocardial injury or AMI are the most apparent complicating factors in many studies of AMI trends.

DelveInsight’s “Acute Myocardial Infarction (AMI)– Epidemiology Forecast – 2034” report delivers an in-depth understanding of AMI, historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

Geography Covered

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2021-2034

Acute myocardial infarction (AMI) Understanding

Acute myocardial infarction (AMI) Overview

Acute myocardial infarction is myocardial necrosis resulting from acute obstruction of a coronary artery. Symptoms include chest discomfort with or without dyspnea, nausea, and/or diaphoresis. Diagnosis is by electrocardiography (ECG) and the presence or absence of serologic markers. Treatment is antiplatelet drugs, anticoagulants, nitrates, beta-blockers, statins, and reperfusion therapy. For ST-segment-elevation myocardial infarction, emergency reperfusion is via fibrinolytic drugs, percutaneous intervention, or, occasionally, coronary artery bypass graft surgery. For non-ST-segment-elevation myocardial infarction, reperfusion is via percutaneous intervention or coronary artery bypass graft surgery.

AMI is one of the leading causes of death in the developed world. AMI can be divided into two categories, non-ST-segment elevation MI (NSTEMI) and ST-segment elevation MI (STEMI). Unstable angina is similar to NSTEMI. However, cardiac markers are not elevated.

AMI Diagnosis

The initial evaluation of a patient with a suspected AMI should include a focused clinical history, physical examination, electrocardiography, cardiac markers, and a chest radiograph. An ECG is especially useful for distinguishing between an NSTEMI and a STEMI. Serum biomarkers of myocardial necrosis include cardiac-specific troponins T and I, MB isoforms of creatine (CK-MB), creatine kinase (CK), and myoglobin. Myocardial injury is diagnosed as wall motion abnormalities on echocardiography. An echocardiogram, however, cannot distinguish between an acute STEMI from an old myocardial scar or severe acute ischemia. Still, ease and safety make it useful as a screening tool to aid management decisions. Several other causes of chest pain can masquerade as a myocardial infarction. Most notable include acute pericarditis, pulmonary embolism, acute aortic dissection, costochondritis, and gastroesophageal reflux disease.

Further details related to diagnosis will be provided in the report…

Acute Myocardial Infarction Epidemiology

The acute myocardial infarction epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by total incident cases of AMI, type-specific incidence of AMI, and gender-specific incidence of AMI covering the United States, EU4 countries (Germany, France, Italy, Spain), and the United Kingdom, and Japan from 2021 to 2034.

• The total incident cases of AMI in the United States are estimated to be nearly 830,000 in 2024. The cases are expected to increase by 2034.
• In EU4 and the UK, the incident cases of AMI were ~400,000 cases in males and ~170,000 cases in females in 2024.
• There were ~47,000 cases of STEMI and ~36,000 cases of NSTEMI in Japan in 2024.           

AMI Report Insights

• Patient population
• Country-wise epidemiology distribution

AMI Report Key Strengths

• Ten-year forecast
• 7MM coverage 
• AMI epidemiology segmentation

FAQs

• What are AMI's disease risks, burdens, and unmet needs? What will be the growth opportunities across the 7MM concerning the patient population with AMI?
• What is the historical and forecasted AMI patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
• At what CAGR is the population expected to grow in the 7MM during the study period (2021-2034)?
• What will be the growth opportunities in the 7MM with respect to the patient population of AMI?

Reasons to Buy

• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand key opinion leaders’ perspectives around the diagnostic challenges to overcome barriers in the future.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.